Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL23668767 | 1.00 | ACHE (0.67) | ACHENPY2R | |
| SCHEMBL3341801 | 0.92 | ACHE (0.68) | ACHE | |
| Zanapezil SCHEMBL1232176 | 0.86 | ACHE (0.91) | ACHE | |
| Zanapezil SCHEMBL1232174 | 0.86 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9203761 | 0.85 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9203739 | 0.85 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL6848789 | 0.85 | ACHE (0.66) | ACHE | |
| Fumaric Acid SCHEMBL9200365 | 0.83 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9200378 | 0.83 | ACHE (0.91) | ACHE | |
| SCHEMBL6262731 | 0.81 | ACHE (0.68) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | claimed |
| US-20190262268-A1 | ORAL MODIFIED RELEASE FORMULATIONS | RUBICON RES PRIVATE LIMITED (IN) | 2019-08-29 | — | — | US | claimed |
| US-20170128379-A1 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-05-11 | — | — | US | claimed |
| WO-2016001937-A2 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230391734-A1 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | NEUROPORE THERAPIES, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11708338-B2 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof | NEUROPORE THERAPIES, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11492348-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | NEUROPORE THERAPIES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | disclosed |
| EP-3946599-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | Neuropore Therapies, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20040258741-A1 | Percutaneous absorption preparations | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1484053-A2 | Percutaneously applicable preparation and suppository containing an antidementia medicament | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-6815454-B2 | DONEPEZIL HYDROCHLORIDE AND A ABSORPTION PROMOTER SELECTED FROM THE GROUP CONSISTING OF A HIGHER ALCOHOL, AN ESTER OF A HIGHER FATTY ACID AND A LOWER ALCOHOL AND AN ESTER OF A FATTY ACID HAVING 6-18 CARBON ATOMS AND PROPYLENE GLYCOL | EISAI CO., LTD. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-6521639-B1 | Donepezil hydrochloride and lactate of a higher alcohol; increased absorption | EISAI CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| US-6372760-B1 | COGNITION ACTIVATORS WITH ORGANIC ACID FOR DONEPEZIL | EISAI CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-1086706-A1 | STABILIZED COMPOSITIONS CONTAINING NOOTROPIC DRUGS | Eisai Co., Ltd. (JP) | 2001-03-28 | — | — | EP | disclosed |
| US-6193993-B1 | Suppository containing an antidementia medicament | EISAI CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0947193-A2 | Percutaneously applicable preparation and suppository containing an antidementia medicament | Eisai Co., Ltd. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ACHE 3040/4885NPY2R 2907/4885 |
| US-20040258741-A1 | Percutaneous absorption preparations | CUTA, CDH1, DSG1 | ACHE 12/4885NPY2R 2963/4885 |
| US-20240043395-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | ACHE 3591/4885NPY2R 4008/4885 |
| US-11492348-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | ATG7, ULK1, BECN1 | ACHE 4852/4885NPY2R 3125/4885 |
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | TLR2, TLR4, TLR3 | ACHE 3887/4885NPY2R 3130/4885 |
| US-11708338-B2 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof | TPMT, ABCB1, DPP8 | ACHE 3365/4885NPY2R 1585/4885 |
| US-20230391734-A1 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | TPMT, ABCB1, DPP8 | ACHE 3365/4885NPY2R 1585/4885 |
| US-20230265086-A1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | ATG7, ULK1, BECN1 | ACHE 4852/4885NPY2R 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.